Published in J Pathol on June 01, 2000
Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS One (2012) 1.01
Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol (2001) 0.95
Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch (2006) 0.91
[Two-photon fluorescence of ocular melanomas. Studies on a new diagnostic method]. Ophthalmologe (2005) 0.83
Identify the signature genes for diagnose of uveal melanoma by weight gene co-expression network analysis. Int J Ophthalmol (2015) 0.80
[Molecular heterogeneity of malignant melanomas]. Pathologe (2007) 0.75
Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res (1995) 1.83
C-reactive protein. A clinical marker in community-acquired pneumonia. Chest (1995) 1.77
Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin (1995) 1.67
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol (2002) 1.49
Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol (1997) 1.47
Phagocyte function and cytokine production in community acquired pneumonia. Thorax (1994) 1.35
Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol (2000) 1.33
Radiological and clinicopathological features of orbital xanthogranuloma. Br J Ophthalmol (2000) 1.32
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer (2011) 1.30
Epidemiological characteristics, predisposing factors and microbiological profiles of infectious corneal ulcers: the Portsmouth corneal ulcer study. Br J Ophthalmol (2009) 1.26
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol (2000) 1.16
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer (2003) 1.16
Prognostic value of measurement of elastosis in breast carcinoma. J Clin Pathol (1981) 1.13
The lens in hereditary hyperferritinaemia cataract syndrome contains crystalline deposits of L-ferritin. Br J Ophthalmol (2000) 1.10
Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med (1994) 1.10
Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs (1998) 1.08
Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer (2007) 1.08
Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry. Int J Lepr Other Mycobact Dis (1985) 1.08
Ring melanoma--a rare cause of refractory glaucoma. Br J Ophthalmol (1999) 1.06
Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer (2011) 1.04
The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs (1997) 1.03
Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol (2005) 1.01
Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation. J Clin Pathol (1994) 0.99
Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol (1993) 0.98
Histological fate of cortical bone autografts in the middle ear. Clin Otolaryngol Allied Sci (1995) 0.97
Primary liposarcoma of the orbit: a clinicopathologic study of seven cases. Ann Diagn Pathol (2001) 0.96
Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol (2002) 0.96
c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol (1999) 0.95
Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. Eye (Lond) (1997) 0.94
Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye (Lond) (2006) 0.93
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer (1999) 0.92
A large rapidly growing pilomatrixoma on a lower eyelid. Br J Ophthalmol (2000) 0.92
Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci (2001) 0.91
Studies of cell death (apoptosis) and cell division in leprosy granulomas. Int J Lepr Other Mycobact Dis (1986) 0.90
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer (2005) 0.90
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer (2010) 0.88
Two unusual osteogenic orbital tumors: presumed parosteal osteosarcomas of the orbit. Ophthalmology (2001) 0.88
New model of conjunctival scarring in the mouse eye. Br J Ophthalmol (1998) 0.88
Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun (1994) 0.87
Transmission and protection in leprosy: indications of the role of mucosal immunity. Lepr Rev (1997) 0.87
Limbal vernal keratoconjunctivitis in the tropics. Ophthalmology (1998) 0.87
TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies. J Biolumin Chemilumin (1995) 0.87
Measurement of phagocyte chemiluminescence in a microtitre plate format. J Immunol Methods (1988) 0.87
The prognostic significance of c-myc oncogene expression in uveal melanoma. Melanoma Res (1998) 0.86
Persistence of acanthamoeba antigen following acanthamoeba keratitis. Br J Ophthalmol (2001) 0.86
The influence of antimycobacterial chemotherapy on delayed hypersensitivity skin-test reactions in leprosy patients. Lepr Rev (1988) 0.86
Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res (2001) 0.86
Multifocal choroiditis: clinicopathologic correlation. Arch Ophthalmol (1998) 0.86
Differential immunoreactivity of melanocytic lesions of the conjunctiva. Histopathology (2001) 0.85
Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis. Br J Ophthalmol (2006) 0.85
Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res (1997) 0.85
Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer (2013) 0.85
The immunoalkaline phosphatase technique in immunohistochemistry: the effect of permanganate-oxalate melanin bleaching upon four final reaction products. Br J Biomed Sci (1996) 0.83
A clinical, histopathological, and genetic study of Avellino corneal dystrophy in British families. Br J Ophthalmol (2003) 0.82
Preservation of keratin expression in oral mucosa using a novel transport medium. J Oral Pathol Med (1992) 0.82
Eye involvement mimicking scleritis in a patient with chronic lymphocytic leukaemia. Br J Ophthalmol (2005) 0.82
Impairment of vasomotor reflexes in the fingertips of leprosy patients. J Neurol Neurosurg Psychiatry (1991) 0.81
The influence of killed Mycobacterium leprae and other mycobacteria on opsonized yeast phagocytosis. Clin Exp Immunol (1986) 0.81
Measurement of phagocyte chemiluminescence using a microtitre plate luminometer. J Biolumin Chemilumin (1989) 0.81
Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Res Treat (1996) 0.81
Observational and cost analysis of the implementation of breast cancer sentinel node intraoperative molecular diagnosis. J Clin Pathol (2010) 0.80
Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. Br J Cancer (2003) 0.80
Blood flow velocity in cutaneous lesions of leprosy. Int J Lepr Other Mycobact Dis (1988) 0.80
Mucosal immunity to mycobacteria in leprosy patients and their contacts. Lepr Rev (1988) 0.79
Histology of xanthelasma lesion treated by argon laser photocoagulation. Eye (Lond) (1998) 0.79
The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anticancer Drugs (1994) 0.79
Abnormalities of the transforming growth factor-beta pathway in ocular melanoma. J Pathol (2000) 0.79
Risk factors for intraocular melanoma and occupational exposure. Br J Ophthalmol (1999) 0.78
The effect of cefodizime on phagocyte function in non-patient volunteers and patients with chronic renal failure. In vitro and ex vivo studies. Int J Clin Lab Res (1996) 0.78
Effect of salmeterol on polymorphonuclear leukocyte (PMNL) chemiluminescence in vitro. J Biolumin Chemilumin (1993) 0.78
The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma. Anticancer Drugs (2000) 0.78
Cystic epithelial ingrowth as a late complication of penetrating keratoplasty. Arch Ophthalmol (1999) 0.77
Monocyte aggregation around agarose beads in collagen gels: a 3-dimensional model of early granuloma formation? J Immunol Methods (1995) 0.77
Recruiting donors for autopsy based cancer research. J Med Ethics (2005) 0.77
Proton beam therapy and iris neovascularisation in uveal melanoma. Eye (Lond) (2005) 0.77
Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma. J Pathol (2000) 0.76
Impairment of fingertip vasomotor reflexes in leprosy patients and apparently healthy contacts. Int J Lepr Other Mycobact Dis (1991) 0.76
TNF and pneumonia. Chest (1994) 0.75
Modelling uveal melanoma. Br J Ophthalmol (1999) 0.75
Rhinostomies: an open and shut case? Br J Ophthalmol (1999) 0.75
Comment: Assessment of histological response to treatment. Lepr Rev (1990) 0.75
Tumor chemosensitivity and chemoresistance assays. Cancer (1996) 0.75
Undefined high-power fields. Lancet (1996) 0.75
A study of the histological basis of textural analysis. Microsc Acta (1981) 0.75
Ex vivo activity of XR5000 against solid tumors. Anticancer Drugs (2000) 0.75
A novel tissue preservation medium for immunoperoxidase staining of skin biopsies. Br J Dermatol (1992) 0.75
The infrastructure of the anterior chamber. Eye (Lond) (1998) 0.75
Heat-stable opsonins in tuberculosis and leprosy. FEMS Immunol Med Microbiol (1993) 0.75
Development of a mucosal challenge test for leprosy using leprosin A. J Immunol Methods (1995) 0.75
Case of thymic parathyroid carcinoma in a haemodialysis patient: application of tumour chemosensitivity testing. J Laryngol Otol (2004) 0.75
Permanent corneal limbal stem cell dysfunction following radiotherapy for orbital lymphoma. Eye (Lond) (2000) 0.75
A poorly differentiated Sertoli-Leydig cell tumour associated with an ovarian sex cord tumour with annular tubules in a woman with Peutz-Jeghers syndrome. Histopathology (1994) 0.75
Successful treatment of multiple drug resistance with ofloxacin in a leprosy patient. Int J Dermatol (1995) 0.75
Tyr-TGFalpha transgenic mice develop ocular melanocytic lesions. Melanoma Res (2002) 0.75
The influence of age and sex on phagocyte chemiluminescence. J Biolumin Chemilumin (1995) 0.75
Osmosin and ileal ulceration: a case report. Scott Med J (1985) 0.75
Measurement of cell migration stimulated by interleukin 8: use of ATP chemiluminescence. Cytokine (1994) 0.75
Comparison of salmeterol with placebo in mild asthma: effect on peripheral blood phagocyte function and cytokine levels. Int Arch Allergy Immunol (1994) 0.75
Antibiotic effects on phagocyte chemiluminescence in vitro. Int J Clin Lab Res (1995) 0.75
Serum antibody responses to mycobacteria in leprosy patients and their contacts. Lepr Rev (1988) 0.75